Acadesine

Summary

Acadesine (CHEMBL1551724) is a phase-3 clinical-stage small-molecule platelet aggregation inhibitor (ATC C01EB13); indicated across 2 conditions including cardiovascular disorder and b-cell chronic lymphocytic leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01EB13
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 258.23 Da · C9H14N4O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1551724
Name	Acadesine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	17513
ChEBI	CHEBI:28498
ATC	C01EB13
Molecular formula	C9H14N4O5
Molecular weight	258.23
InChIKey	RTRQQBHATOEIAF-UUOKFMHZSA-N

SMILES: C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N

IUPAC name: 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide

ChEBI definition: A 1-ribosylimidazolecarboxamide in which the carboxamide group is situated at position 4 of the imidazole ring, which is further substituted at position 5 by an amino group. A purine nucleoside analogue and activator of AMP-activated protein kinase, it is is used for the treatment of acute lymphoblastic leukemia and is reported to have cardioprotective effects.

Pharmacological roles (ChEBI): platelet aggregation inhibitor, antineoplastic agent.

Also known as: Acadesina, Acadesine, NSC-105823, SID29217492, ACADESINE, SID124893186, SID170465608, SID144205104, acadesine 5’-monophosphate, AICAR (ACADESINE), AICAR (Acadesine)

Patent coverage: 1,111 distinct patent families (3,139 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	AMP kinase	Activation

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00872001	PHASE3	TERMINATED	The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)
NCT00559624	PHASE1/PHASE2	COMPLETED	Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients
NCT01813838	PHASE1/PHASE2	TERMINATED	GFM-Acadesine: A Phase I-II Trial of Acadesine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).